This study examined bacteriostatic and bactericidal activities of oral and parenteral antibiotics for penicillin-susceptible and intermediately and fully penicillin-resistant pneumococci. ␤-Lactamase inhibitors did not affect ␤-lactam results. The activities of ampicillin, amoxicillin ؎ clavulanate, WY-49605, cefuroxime, cefpodoxime, cefdinir, cefixime, and cefaclor against two penicillin-susceptible, two intermediately penicillin-resistant, and two fully penicillin-resistant pneumococcal strains were tested. For all three groups, bacteriostatic values of amoxicillin and WY-49605 were lower than were those of other ␤-lactams tested. Of the cephalosporins, cefdinir, cefuroxime, and cefpodoxime yielded the lowest bacteriostatic values. All ␤-lactams were bactericidal (reduced original counts by >3 log 10 CFU/ml) at 1 dilution above bacteriostatic values, except for cefpodoxime (bactericidal at 2 dilutions above bacteriostatic values for one susceptible strain and one intermediately resistant strain), cefuroxime (bactericidal at 2 dilutions above bacteriostatic values for one intermediately resistant strain), and ampicillin (bactericidal at 2 dilutions above bacteriostatic values for one intermediately resistant strain). The activities of piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillinclavulanate, ampicillin, ampicillin-sulbactam, ceftriaxone, ceftazidime, and ciprofloxacin against four penicillin-susceptible, two intermediately penicillin-resistant, and four fully penicillin-resistant pneumococcal strains were evaluated. Bacteriostatic values of piperacillin, ampicillin, and ceftriaxone for all groups were lower than were those of ticarcillin and ceftazidime. Bacteriostatic values of ciprofloxacin were unaffected by penicillin susceptibility. All ␤-lactams were bactericidal at 1 dilution above the bacteriostatic value, except for piperacillin (bactericidal at 2 dilutions above the bacteriostatic value for one intermediately resistant strain), ticarcillin (bactericidal at 2 dilutions above the bacteriostatic value for one susceptible strain and one resistant strain), ampicillin (bactericidal at 2 dilutions above the bacteriostatic value for two resistant strains), ceftriaxone (bactericidal at 2 dilutions above the bacteriostatic value for one resistant strain), and ceftazidime (bactericidal at 2 dilutions above the bacteriostatic value for one susceptible strain).
The worldwide incidence of infections caused by pneumococci resistant to penicillin G and other antimicrobial agents has increased at an alarming rate during the past 2 decades and in particular the past 5 years (1). The main foci of penicillinresistant pneumococci are currently South Africa, Spain, and Eastern Europe. However, wherever susceptibility testing is performed by appropriate methods, resistant strains are almost universally found (1) . The spread of penicillin-resistant clones from country to country and from continent to continent demonstrates the capability of these strains to spread rapidly throughout the world (16, 17) . In the United States, recent surveys (4, 29) have shown an increase in resistance to penicillin from Ͻ5% before 1989 (including Ͻ0.02% of isolates for which MICs are Ն2.0 g/ml) to 6.6% in 1991 and 1992 (with 1.3% of isolates requiring MICs of Ն2.0 g/ml). The problem has recently been exacerbated by the appearance of pneumococci with high-level resistance to cefotaxime and ceftriaxone (3, 6, 23) .
Although nonmeningeal infections caused by intermediately and fully penicillin-resistant pneumococci may be treated parenterally under certain conditions with high doses of penicillin and other ␤-lactams, treatment may not always be successful. By contrast, clinical failure of penicillin in treatment of meningitis caused by strains intermediately resistant to penicillin approaches 80%, and very few cases of meningitis caused by strains fully resistant to penicillin have responded to penicillin therapy (8, 9, 31) . There is currently no standardized oral therapy for otitis media caused by intermediately and fully penicillin-resistant pneumococci (8, 9) .
The distribution of resistant strains is highly variable in the United States. Block and coworkers (2) have recently reported a 28% incidence rate of penicillin-resistant pneumococci from middle ear fluid of children with acute otitis media in Kentucky and a 29% incidence level of these strains in nasopharyngeal cultures from children with otitis media in Tennessee.
There is an urgent need for oral and parenteral ␤-lactams which can be used for infections such as meningitis, bacteremia, pneumonia, bronchitis, sinusitis, and otitis media caused by intermediately and fully penicillin-resistant pneumococci. Previous studies have documented relatively high MICs of all groups of oral cephalosporins for these strains, with cefdinir, cefuroxime, and cefpodoxime yielding the lowest MICs for the group (7, 15, 19, 22, 27, 28, 30) . Amoxicillin has MICs lower than those of penicillin G, ampicillin, and oral cephalosporins for these strains (7, 22, 27) . WY-49605, a new broad-spectrum penem, has MICs 1 or 2 dilutions lower than those of amoxicillin for penicillin-susceptible and -resistant pneumococci (27) . Previous studies have confirmed the low MICs of piperacillin compared with those of ticarcillin and ceftazidime for penicillin-susceptible and intermediately and fully penicillinresistant pneumococci (21, 31, 32) .
The present study confirms and extends the above-described findings, by examining the bacteriostatic and bactericidal ac-tivities of (i) penicillin G, ampicillin, amoxicillin Ϯ clavulanate, WY-49605, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir for two penicillin-susceptible, two intermediately penicillin-resistant, and two fully penicillin-resistant pneumococcal strains and (ii) piperacillin Ϯ tazobactam, ticarcillin Ϯ clavulanate, ampicillin Ϯ sulbactam, ceftriaxone, ceftazidime, and ciprofloxacin for four penicillin-susceptible, two intermediately resistant, and four fully resistant pneumococcal strains.
MATERIALS AND METHODS
Bacterial strains. Pneumococcal strains tested are listed in the tables. All were clinical isolates. Penicillin MICs for susceptible strains were Յ0.06 g/ml, those for intermediately resistant strains were 0.1 to 1.0 g/ml, and those for resistant strains were Ն2.0 g/ml. Organisms were stored at Ϫ70ЊC in double-strength skim milk (Difco Laboratories, Detroit, Mich.) and subcultured three times on Trypticase soy agar-5% sheep blood plates (BBL Microbiology Systems, Detroit, Mich.) before testing.
Antimicrobial agents. Antimicrobial powers for susceptibility testing were obtained from their respective manufacturers.
MIC determination. MICs were determined by the agar dilution method as described previously (12) using Mueller-Hinton agar (BBL) supplemented with 5% sheep blood. Clavulanate was combined with amoxicillin and sulbactam was combined with ampicillin at 1:2 ratios. Clavulanate was added to ticarcillin at a fixed concentration of 2.0 g/ml, and tazobactam was added to piperacillin at a fixed concentration of 4.0 g/ml. Suspensions with a turbidity equal to a 0.5 McFarland standard were prepared by suspending growth from overnight Trypticase soy agar-5% sheep blood plates in 2 ml of Mueller-Hinton broth (Difco). Suspensions were further diluted in broth to obtain a final inoculum of approximately 10 4 organisms per spot. Plates were inoculated with a Steers replicator and 3-mm inoculating pins and incubated overnight in ambient air at 35ЊC. The lowest concentration of antibiotic showing no growth was defined as the MIC. A faint haze or one colony on the inoculum was ignored. Standard quality control strains, including Streptococcus pneumoniae ATCC 49619 (18) , were included in each run.
Bacteriostatic and bactericidal studies. Glass tubes containing 5 ml of cationadjusted Mueller-Hinton broth (Difco) plus 5% lysed horse blood with doubling antibiotic concentrations were inoculated with approximately 5 ϫ 10 5 CFU/ml (1 ϫ 10 5 to 1 ϫ 10 6 CFU/ml) and incubated at 35ЊC in a shaking water bath (20) .
Antibiotic concentrations were chosen to comprise 3 doubling dilutions above and 4 dilutions below the agar dilution MIC.
Lysed horse blood was prepared by freezing and thawing horse blood (Cleveland Scientific, Bath, Ohio) eight times. Equal volumes of lysed blood and sterile deionized water were then mixed and centrifuged at 12,000 ϫ g for 20 min. Appropriate amounts of 50% lysed blood were then added to the cation-adjusted Mueller-Hinton broth to yield a final concentration of 5% lysed horse blood. The bacterial inoculum was prepared by diluting a 16-h broth (medium as described above) culture in the same medium. Dilutions required to obtain the correct inoculum (10 5 to 10 6 CFU/ml) were determined by prior viability studies using each strain.
To inoculate each tube of serially diluted antibiotic, 50 l of diluted inoculum was delivered by pipette beneath the surface of the broth, then vortexed, and plated for viability counts (0 h). Only tubes containing an initial inoculum within the range of 10 5 to 10 6 CFU/ml were acceptable. Viability counts of antibiotic-containing suspensions were performed at 0, 6, 12, and 24 h by plating 10-fold dilutions of 0.1-ml aliquots from each tube in sterile Mueller-Hinton broth onto Trypticase soy agar-5% sheep blood agar plates (BBL). Recovery plates were incubated for up to 48 h. Colony counts were performed on plates yielding 30 to 300 colonies.
Bacteriostatic and bactericidal values were determined at 24 h, for strains which did not autolyse (20) . Decreases in viability at 24 h, which were also seen in the drug-free controls due to autolysis, were disregarded. The bacteriostatic value (also taken as the broth MIC) was defined as the lowest concentration of antibiotic which inhibited bacterial growth. Antibiotics were considered to be bactericidal at the lowest concentration that reduced the original inoculum by Ն3 log 10 CFU/ml at 24 h.
RESULTS
Results of bacteriostatic and bactericidal testing of oral and parenteral ␤-lactams and ciprofloxacin are presented in Tables  1 and 2 . Agar dilution MICs were also determined (data not shown) and compared with bacteriostatic values from growth curves. In all organism-antimicrobial agent combinations tested by agar and broth methodology, MICs were all within 1 doubling dilution. In all tests, the presence or absence of a ␤-lactamase inhibitor did not significantly affect the result obtained with the antibiotic alone (11) . As can be seen from Table 1 , bacteriostatic values for penicillin-susceptible and intermediately and fully penicillin-resistant pneumococci were all lower for amoxicillin and WY-49605 than for other oral ␤-lactams tested. Amoxicillin bacteriostatic levels were 1 to 3 dilutions lower than those of penicillin G and ampicillin in intermediately resistant and resistant strains. Cefdinir, cefuroxime, and cefpodoxime yielded the lowest cephalosporin bacteriostatic levels, with cefaclor and cefixime yielding higher values. Levels of cefdinir, cefuroxime, and cefpodoxime were Ն1 dilution higher than those of amoxicillin for most strains.
Examples of results for one intermediately penicillin-resistant organism (strain 5) are presented in Fig. 1 , and bactericidal values of oral agents for all strains are presented in Table  1 . Bacteriostatic and bactericidal values were generally identical for the two penicillin-susceptible strains and tended to differ by 1 dilution for three of the four intermediately resistant and resistant strains. All oral ␤-lactams were bactericidal at 1 dilution above the MIC, except for cefpodoxime (bactericidal at 2 dilutions above the bacteriostatic level for one penicillinsusceptible strain and one intermediately penicillin-resistant strain), cefuroxime (bactericidal at 2 dilutions above the bacteriostatic level for one intermediately penicillin-resistant strain), and ampicillin (bactericidal at 2 dilutions above the bacteriostatic level for one intermediately penicillin-resistant strain).
As can be seen from Table 2 , bacteriostatic values of parenteral agents for all pneumococcal groups were lower for piperacillin (susceptible, 0.016 to 0.032 g/ml; intermediately resistant, 0.125 to 1.0 g/ml; resistant, 4.0 g/ml), ampicillin (susceptible, 0.016 to 0.032 g/ml; intermediately resistant, 0.064 to 0.125 g/ml; resistant, 1.0 to 2.0 g/ml), and ceftriaxone (susceptible, 0.008 to 0.016 g/ml; intermediately resistant, 0.064 g/ml; resistant, 0.5 to 2.0 g/ml) than for ticarcillin (susceptible, 0.5 to 1.0 g/ml; intermediately resistant, 8.0 to 32.0 g/ml; resistant, 64.0 to 128.0 g/ml) and ceftazidime (susceptible, 0.064 to 0.125 g/ml; intermediately resistant, 1.0 to 2.0 g/ml; resistant, 8.0 to 32.0 g/ml). Bacteriostatic values for ciprofloxacin (0.5 to 2.0 g/ml) were unaffected by penicillin susceptibility.
All parenteral ␤-lactams were bactericidal (reduced colony counts by Ն3 log 10 CFU/ml) at 1 dilution above the bacteriostatic value, except for piperacillin (bactericidal at 2 dilutions above the bacteriostatic level for one intermediately resistant strain), ticarcillin (bactericidal at 2 dilutions above the bacteriostatic level for one susceptible strain and one resistant strain), ampicillin (bactericidal at 2 dilutions above the bacteriostatic level for two resistant strains), ceftriaxone (bactericidal at 2 dilutions above the bacteriostatic level for one resistant strain), and ceftazidime (bactericidal at 2 dilutions above the bacteriostatic level for one susceptible strain).
DISCUSSION
Studies of bacteriostatic and bactericidal levels are useful methods to examine the kinetic interaction between bacteria and antimicrobial agents. The viable-count threshold of a 0.1-ml aliquot placed on a plate is theoretically 10 CFU/ml if one colony grows; however, for statistical accuracy the lower limit has been set at 30 colonies (300 CFU/ml, as in our study) (14) , and this threshold was therefore used in all experiments. The problem of drug carryover was also addressed: we believe that spreading 0.1 ml of undiluted broth onto a plate containing 25 ml of medium would dilute the drug 1:250, further 10-fold dilutions would dilute drugs 1:2,500 and 1:25,000, etc. With the concentrations of drugs used, only undiluted inocula would have had any potential for drug carryover, and only low counts (Ͻ1,000 CFU/ml) would be likely to be affected. We therefore feel that drug carryover was not a confounding factor in data generation. Irreversible drug binding could have played a role but would have occurred regardless of the method used. Because of the correspondence between agar dilution MICs and bacteriostatic values in the present study, we feel confident of the accuracy of our methodology.
Results of this study confirm the improved activity of amoxicillin compared with those of penicillin G, ampicillin, and the oral cephalosporins reported in MIC studies (7, 22, 27) . When agar dilution MICs were compared with bacteriostatic levels in broth, results either were identical or differed only by 1 dilution. With one exception (strain 42), the penicillin susceptibility category of the strains remained the same. Results showed that of all oral ␤-lactams tested in the present study, amoxicillin and WY-49605 yielded the lowest bacteriostatic and bactericidal levels for all strains tested. In contrast to findings by Smith and coworkers (24) that clavulanate significantly enhanced amoxicillin in an experimental rat respiratory tract model, no difference was observed in amoxicillin bacteriostatic and bactericidal levels after addition of clavulanate to amoxicillin.
Results of oral cephalosporins mirrored those obtained in previous MIC testing studies (7, 15, 19, 22, 27, 28, 30) , with cefuroxime, cefdinir, and cefpodoxime yielding the greatest activity. Cefpodoxime, although yielding relatively low bactericidal levels, was sometimes bactericidal only at Ն2 dilutions above the bacteriostatic level. All oral cephalosporins were active against penicillin-susceptible pneumococci.
Several factors should be borne in mind when decisions on oral therapeutic modalities for infections caused by penicillinsusceptible and -resistant pneumococci are made. Apart from cefuroxime axetil (susceptible, Յ0.5 g/ml; intermediately susceptible, 1.0 g/ml; resistant, Ն2.0 g/ml), there are currently no approved National Committee on Clinical Laboratory Standards oral ␤-lactam breakpoints for pneumococci (18) . In addition to results of in vitro susceptibility assays, human pharmacokinetic data for serum and the middle ear (where available) are also important (19) .
There are currently no definitive data on which to base treatment of otitis media associated with penicillin-resistant pneumococci (8, 9) , although amoxicillin is still regarded as the ␤-lactam of choice (8) . Erythromycin and trimethoprim-sulfamethoxazole are currently recommended non-␤-lactams; however, increased resistance to both these agents is being reported in many countries, and there is an urgent need for a reliable oral agent to treat these infections (8, 9) .
Cohen et al. (5), in a study in which specimens were obtained by myringotomy or from ruptured tympanic membranes, recently reported that intermediately and fully penicillin-resistant strains were isolated significantly less often from patients taking amoxicillin or amoxicillin-clavulanate than from those taking cefixime (P ϭ 0.0001), erythromycin-sulfisoxazole (P ϭ 0.0001), or cefaclor (P ϭ 0.029). Gehanno and coworkers (10) have found clinical success rates of 93% (39 of 42 cases), 91% (10 of 11 cases), and 75% (24 of 32 cases) with oral cefuroxime axetil treatment of otitis media associated with penicillin-susceptible, intermediately penicillin-resistant, and penicillin-resistant pneumococci, respectively. However, numbers in the intermediately resistant category were small. No other studies with any other oral cephalosporins against otitis media caused by penicillin-resistant pneumococci are currently available.
Lower MICs of piperacillin for penicillin-susceptible, intermediately penicillin-resistant, and penicillin-resistant pneumococci compared with those of ticarcillin Ϯ clavulanate and ceftazidime have been reported before, both by us (21) other workers (31, 32) . High MICs of ceftazidime, in contrast to lower MICs of ceftriaxone for intermediately and fully resistant pneumococcal strains, have also previously been described (15, 26, 31) . MICs of ampicillin are similar to those reported previously (7, 22) . The present study confirms and extends the above-described findings. Most penicillin-resistant pneumococci isolated in the United States are of the intermediately resistant variety (1, 8, 9) . In view of the pharmacokinetic findings of Sörgel and Kinzig (25) , serum piperacillin levels well above the agar dilution MIC and bacteriostatic and bactericidal levels can certainly be achieved for intermediately penicillin-resistant and possibly also penicillin-resistant pneumococci. Although in vitro results for ampicillin were similar to those for piperacillin, pharmacokinetics of piperacillin are more favorable, pointing to higher levels in serum than those of ampicillin (13, 25) .
Data for ceftriaxone obtained in this study further support use of this compound for systemic infections (including meningitis) caused by intermediately penicillin-resistant pneumococci (15, 26, 31) . However, with a resistance breakpoint of Ն2.0 g/ml (18), the bacteriostatic and bactericidal values for two of four penicillin-resistant strains, and the bactericidal value for a third resistant strain, were in the ceftriaxone-resistant category.
Data for ciprofloxacin indicate that bacteriostatic and bactericidal levels cluster around the susceptibility breakpoint: this and other currently available quinolones such as ofloxacin should not be used as first-line treatment of systemic pneumococcal infections caused by penicillin-susceptible or -resistant strains (8, 9, 28) .
There are currently no breakpoints for pneumococci recommended by the National Committee for Clinical Laboratory Standards for the parenteral ␤-lactams tested in this study other than ceftriaxone (18) . In view of the rapid worldwide spread of penicillin-resistant strains, development of breakpoints for these agents is clearly needed. Bacteriostatic and bactericidal levels of piperacillin for resistant pneumococci are lower than reported levels in serum and tissue (25) : this is particularly true for intermediately resistant strains, which compose Ͼ90% of pencillin-resistant pneumococci isolated in the United States (1, 4) . Additionally, in view of favorable pharmacokinetic data, serum piperacillin levels sufficient to inhibit intermediately and possibly fully resistant organisms may be achievable in humans.
It is important to note that for most antibiotics tested, activity against penicillin-resistant strains was clearly lower than activity against intermediately penicillin-resistant pneumococci. Therefore, possible use of such agents for treatment of infections caused by pneumococci for which MICs are Ն2.0 g/ml cannot be recommended at this time.
In summary, on the basis of MICs and studies of bacteriostatic and bactericidal levels, including results presented in this paper, all oral compounds tested are potentially of use in conditions such as otitis media in areas where intermediately penicillin-resistant pneumococci are uncommon. However, in areas where these strains are frequently found, amoxicillin Ϯ clavulanate may be a logical choice, based on favorable susceptibility kinetics, the lowest MICs of all currently available oral ␤-lactams for penicillin-susceptible and intermediately penicillin-resistant pneumococci, and activity against Haemophilus influenzae and Moraxella catarrhalis. Cefuroxime and cefpodoxime may also be of use, although their bacteriostatic levels are higher than those of amoxicillin. WY-49605 is of potential interest but requires human pharmacokinetic and clinical studies. Cefuroxime, cefpodoxime, and WY-49605 are also active against H. influenzae and M. catarrhalis. Piperacillin Ϯ tazobactam may represent an alternative to cefotaxime or ceftriaxone, for therapy of systemic nonmeningeal infections caused by these strains. Clinical studies will be necessary to prove the above hypotheses and also to delineate the role of these compounds in treatment of infections caused by penicillin-resistant pneumococci.
